Boston Scientific has launched DIRECTSENSE Technology, a tool to monitor the effect of radio frequency (RF) energy delivery during cardiac ablation procedures.
Launched in the US, the tool received the US Food and Drug Administration (FDA) approval in April and is available on the RHYTHMIA HDx Mapping System.
It is considered to be the only tool to monitor changes in local impedance – electrical resistance – around the tip of the INTELLANAV MiFi Open-Irrigated (OI) ablation catheter.
Furthermore, the tool provides the clinician with an additional measurement of therapy effect during the ablation procedure.
